717 related articles for article (PubMed ID: 18653492)
1. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.
Staals LM; Snoeck MM; Driessen JJ; Flockton EA; Heeringa M; Hunter JM
Br J Anaesth; 2008 Oct; 101(4):492-7. PubMed ID: 18653492
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
Flockton EA; Mastronardi P; Hunter JM; Gomar C; Mirakhur RK; Aguilera L; Giunta FG; Meistelman C; Prins ME
Br J Anaesth; 2008 May; 100(5):622-30. PubMed ID: 18385265
[TBL] [Abstract][Full Text] [Related]
3. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial.
de Souza CM; Tardelli MA; Tedesco H; Garcia NN; Caparros MP; Alvarez-Gomez JA; de Oliveira Junior IS
Eur J Anaesthesiol; 2015 Oct; 32(10):681-6. PubMed ID: 26225497
[TBL] [Abstract][Full Text] [Related]
5. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
6. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
Jones RK; Caldwell JE; Brull SJ; Soto RG
Anesthesiology; 2008 Nov; 109(5):816-24. PubMed ID: 18946293
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment.
Panhuizen IF; Gold SJ; Buerkle C; Snoeck MM; Harper NJ; Kaspers MJ; van den Heuvel MW; Hollmann MW
Br J Anaesth; 2015 May; 114(5):777-84. PubMed ID: 25829395
[TBL] [Abstract][Full Text] [Related]
8. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.
Shields M; Giovannelli M; Mirakhur RK; Moppett I; Adams J; Hermens Y
Br J Anaesth; 2006 Jan; 96(1):36-43. PubMed ID: 16357116
[TBL] [Abstract][Full Text] [Related]
9. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex.
Staals LM; Driessen JJ; Van Egmond J; De Boer HD; Klimek M; Flockton EA; Snoeck MM
Acta Anaesthesiol Scand; 2011 Jul; 55(6):700-7. PubMed ID: 21574968
[TBL] [Abstract][Full Text] [Related]
10. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial.
Czarnetzki C; Tassonyi E; Lysakowski C; Elia N; Tramèr MR
Anesthesiology; 2014 Jul; 121(1):59-67. PubMed ID: 24608361
[TBL] [Abstract][Full Text] [Related]
12. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
Sorgenfrei IF; Norrild K; Larsen PB; Stensballe J; Ostergaard D; Prins ME; Viby-Mogensen J
Anesthesiology; 2006 Apr; 104(4):667-74. PubMed ID: 16571960
[TBL] [Abstract][Full Text] [Related]
13. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.
Wu X; Oerding H; Liu J; Vanacker B; Yao S; Dahl V; Xiong L; Claudius C; Yue Y; Huang Y; Abels E; Rietbergen H; Woo T
BMC Anesthesiol; 2014; 14():53. PubMed ID: 25187755
[TBL] [Abstract][Full Text] [Related]
14. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I
Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of sugammadex in the reversal of neuromuscular blockade induced by rocuronium in long-duration surgery: under inhaled vs. intravenous anesthesia].
Veiga-Ruiz G; Domínguez N; Orozco J; Janda M; Hofmockel R; Alvarez-Gómez JA
Rev Esp Anestesiol Reanim; 2009; 56(6):349-54. PubMed ID: 19725342
[TBL] [Abstract][Full Text] [Related]
16. Use of sugammadex in patients with a history of pulmonary disease.
Amao R; Zornow MH; Cowan RM; Cheng DC; Morte JB; Allard MW
J Clin Anesth; 2012 Jun; 24(4):289-97. PubMed ID: 22608583
[TBL] [Abstract][Full Text] [Related]
17. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: A randomized comparison of sugammadex reversal with spontaneous recovery.
Rahe-Meyer N; Berger C; Wittmann M; Solomon C; Abels EA; Rietbergen H; Reuter DA
Anaesthesist; 2015 Jul; 64(7):506-12. PubMed ID: 26126940
[TBL] [Abstract][Full Text] [Related]
18. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
19. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients.
Suzuki T; Kitajima O; Ueda K; Kondo Y; Kato J; Ogawa S
Br J Anaesth; 2011 Jun; 106(6):823-6. PubMed ID: 21531745
[TBL] [Abstract][Full Text] [Related]
20. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
